Skip to main
STRO
STRO logo

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 50%
Sell 17%
Strong Sell 0%

Bulls say

Sutro Biopharma Inc is currently advancing several promising biopharmaceutical products, highlighted by an increased valuation of STRO-004 to $50 million based on strong preclinical data and upcoming IND filing. The company has demonstrated significant improvements in overall survival and progression-free survival metrics for its Tivdak product, suggesting its competitive therapeutic potential in metastatic cervical cancer. Additionally, the pipeline encompasses various candidates targeting multiple cancers, reflecting a diverse approach to addressing significant unmet medical needs in oncology and autoimmune disorders.

Bears say

Sutro Biopharma faces significant challenges due to the limitations of its antibody candidates, particularly their preferential binding to specific conformations, which hinders uniform tumor targeting and affects the overall performance of antibody-drug conjugates (ADCs). The complexities surrounding suboptimal binding impact crucial factors such as internalization, payload delivery, and efficacy, potentially undermining the therapeutic effectiveness of its pipeline products. Additionally, adverse effects observed with similar targeting strategies, such as off-tissue toxicity associated with Tivdak, raise concerns about the safety and acceptability of Sutro's therapies in clinical applications.

STRO has been analyzed by 6 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Hold based on their latest research and market trends.

According to 6 analysts, STRO has a Hold consensus rating as of Dec 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.